Biocon’s launch of the world’s first bio-similar of Trastuzumab, a critical breast cancer drug, is unlikely to benefit patients in a big way if the company sticks to the prices it has indicated, claimed health activists on Monday. They allege that Roche, which retails the drug at . 75,000 for 440 mg vial, sells it at a discount to its long-term patients through many of its dealers for . 55,000-57,000. Biocon’s retail price of . 56,000 per 440 mg vial doesn’t make the drug much cheaper.
Source: The Times of India
News on Other Repro Health
This is a collection of news clippings from differnt newspapers on other reproductive health issues